Treatment of Pneumonia Patients with Levofloxacin combined with Moxibustion
This study was to investigate the effects of levofloxacin on inflammatory factors and clinical outcomes in patients with community acquired pneumonia. Both groups were given routine treatment, the control group was given azithromycin treatment, and the observation group was given moxibustion treatment on the basis of the control group. The clinical efficacy, the disappearance time of clinical symptoms and the levels of inflammatory factors before and after treatment were compared between the two groups. The results showed that the total effective rates of the observation group and the control group were 94% and 78% respectively, and the difference was statistically significant (P<0.05). The disappearance time of wheezing sound, lung rale, expectoration and fever in the observation group were (5.760.35), (3.120.19), (3.460.37), (1.550.12) days respectively, which were significantly shorter than those in the control group (8.450.64), (5.480.51), (5.06 0.37), (3.140.28) days, with statistical difference (P<0.05). After treatment, the levels of matrix metalloproteinase-2 (MMP-2), procalcitonin (PCT), interleukin-5 (IL-5) and tumor necrosis factor-alpha (TNFalpha) in the two groups were significantly lower than those before treatment, and the decrease of patients in the observation group was significantly greater than that in the control group. ConclusionThe clinical effect of levofloxacin combined with Moxibustion in the treatment of pneumonia is satisfactory, and it can significantly control the level of inflammatory factors in patients, so it is worthy of clinical promotion.